文献速递临床试验与 GCP

低剂量多巴酚丁胺用于急性心肌梗死伴心源性休克中高危患者(DOBERMANN-D试验):双盲、安慰剂对照、单中心、随机临床试验的研究方案

Low-dose dobutamine in acute myocardial infarction with intermediate to high risk of cardiogenic shock development (the DOBERMANN-D trial): study protocol for a double-blinded, placebo-controlled, single-center, randomized clinical trial.
PubMed 文献 · Trials · 2024-10-30

DOBERMANN-D试验为研究者发起的双盲、安慰剂对照、单中心随机临床试验,计划纳入100例≥18岁、入院时无心源性休克且院内休克发生风险中高危(ORBI风险评分≥10)的急性心肌梗死患者,在急诊PCI后24小时内随机给予24小时静脉输注多巴酚丁胺5 μg/kg/min或安慰剂(氯化钠),主要结局为输注后48小时内血浆proBNP峰值作为血流动力学状态的替代指标。

要点

  • 研究纳入急性心肌梗死且ORBI风险评分≥10的院内休克中高危患者100例。
  • 干预为PCI后24小时静脉输注多巴酚丁胺5 μg/kg/min或安慰剂,1:1随机。
  • 主要结局为输注后48小时内血浆proBNP峰值,作为血流动力学状态的替代指标。

核心结论

  • 在急性心肌梗死、接受急诊PCI且院内CS中高危患者中,早期低剂量多巴酚丁胺正性肌力支持可能作为促进血流动力学稳定和患者恢复的干预措施。
  • 其效果将通过proBNP作为CS发生的替代标志物、血流动力学测量以及初始48小时内和3个月随访时重复的TTE进行评估。

研究设计与样本

  • 研究者发起的双盲、安慰剂对照、随机、单中心临床试验。
  • 计划纳入100例≥18岁、入院时无心源性休克且院内CS发生风险中高危(ORBI风险评分≥10)的急性心肌梗死患者。
  • 患者按1:1随机接受24小时静脉输注多巴酚丁胺5 μg/kg/min或安慰剂(氯化钠),于急性PCI后(症状发作<24小时)给药。
  • 在包括研究入组时(输注前)、12、24、36和48小时的时间点采集血样。

主要发现

  • 主要结局为输注后48小时内血浆proBNP峰值,作为血流动力学状态的替代指标。
  • 输注后48小时内通过脉率、血压和乳酸评估血流动力学功能,并在24-48小时后及3个月随访时进行经胸超声心动图(TTE)。
  • 将评估心肌损伤标志物(肌钙蛋白T和肌酸激酶MB(CK-MB))。

关键数值与推荐

  • ORBI风险评分≥10定义院内CS发生风险中高危。
  • 多巴酚丁胺剂量为5 μg/kg/min,静脉输注24小时。
  • 急性PCI在症状发作<24小时内进行。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cardiogenic shock (CS) occurs in 5-10% of patients with acute myocardial infarction (AMI), and the condition is associated with a 30-day mortality rate of up to 50%. Most of the AMI patients are in SCAI SHOCK stage B upon hospital arrival, but some of these patients will progression through the stages to overt shock (SCAI C-E). Around one third of patients who develop CS are not in shock at the time of hospital admission. Pro-B-type natriuretic peptide (proband) is a biomarker closely related to CS development. The aim of this study is to investigate the potential for preventing progression of hemodynamic instability by early inotropic support with low-dose dobutamine infusion administrated after revascularization in AMI patients with intermediate to high risk of in-hospital CS development. METHODS: This investigator-initiated, double-blinded, placebo-controlled, randomized, single-center, clinical trial will include 100 AMI patients (≥ 18 years) without CS at hospital admission and at intermediate-high risk of in-hospital CS development (ORBI risk score ≥ 10). Patients will be randomized in a 1:1 ratio to a 24 h intravenous (IV) infusion of dobutamine (5 μg/kg/min) or placebo (NaCl) administrated after acute percutaneous coronary intervention (PCI) (< 24 h from symptom onset). Blood samples are drawn at time points from study inclusion (before infusion, 12, 24, 36, and 48 h). The primary outcome is peak plasma proBNP within 48 h after infusion as a surrogate-measure for the hemodynamic status. Hemodynamic function will be assessed pulse rate, blood pressure, and lactate within 48 h after infusion and by transthoracic echocardiography (TTE) performed after 24-48 h and at follow-up after 3 months. Markers of cardiac injury (troponin T and creatine kinase MB (CK-MB)) will be assessed. DISCUSSION: Early inotropic support with low-dose dobutamine infusion in patients with AMI, treated with acute PCI, and at intermediate-high risk of in-hospital CS may serve as an intervention promoting hemodynamic stability and facilitating patient recovery. The effect will be assessed using proBNP as a surrogate marker of CS development, hemodynamic measurements, and TTE within the initial 48 h and repeated at a 3-month follow-up. TRIAL REGISTRATION: The Regional Ethics Committee : H-21045751. EudraCT: 2021-002028-19. CLINICALTRIALS: gov: NCT05350592, Registration date: 2022-03-08. WHO Universal Trial Number: U1111-1277-8523.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Holle SLD, Kunkel JB, Hassager C, et al. Low-dose dobutamine in acute myocardial infarction with intermediate to high risk of cardiogenic shock development (the DOBERMANN-D trial): study protocol for a double-blinded, placebo-controlled, single-center, randomized clinical trial. Trials. 2024. PMID: 39478521. doi:10.1186/s13063-024-08567-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。